Description
Lansoprazole is a proton pump (H+/K+ ATPase) inhibitor (PPI) that exhibits antacid and anti-inflammatory activities. Lansoprazole is clinically used to treat gastroesophageal reflux disease (GERD). Lansoprazole inhibits indomethacin-induced gastric damage by preventing activation of mitochondria- and Fas-mediated apoptosis signaling pathways. Lansoprazole also inhibits PMA-induced activation of ERK1/2 and LPS-induced activation of p38 MAPK in neutrophils and decreases levels of pro-inflammatory cytokines in macrophages.
References
Koshio O, Tansho S, Ubagai T, et al. Suppression of phosphorylation of extracellular-signal-regulated kinase and p38 mitogen-activated protein kinase in polymorphonuclear leukocytes by the proton pump inhibitor lansoprazole. J Infect Chemother. 2010 Apr;16(2):100-6. PMID: 20094750.
Maity P, Bindu S, Choubey V, et al. Lansoprazole protects and heals gastric mucosa from non-steroidal anti-inflammatory drug (NSAID)-induced gastropathy by inhibiting mitochondrial as well as Fas-mediated death pathways with concurrent induction of mucosal cell renewal. J Biol Chem. 2008 May 23;283(21):14391-401. PMID: 18375387.
Hinoki A, Yoshimura K, Fujita K, et al. Suppression of proinflammatory cytokine production in macrophages by lansoprazole. Pediatr Surg Int. 2006 Nov;22(11):915-23. PMID: 16932910.
Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004 Jun 30;126(25):7800-11. PMID: 15212527.
